BUSINESS
Atul: Why investors should turn cautious
High-cost inventory of raw materials is a key worry when global growth is faltering
BUSINESS
European energy crisis: Gains and pains for Indian chemical players
Force majeure in European Chemicals industry can lead to significant shortfall in range of chemicals
BUSINESS
Aarti Industries: Capex cycle may turn out to be a growth tonic
Near-term challenge impacting the company’s performance is the shortage of key raw material nitric acid. This can be troubling for the next 6-12 months till the time new domestic capacities go on stream
BUSINESS
Balaji Amines: Spot the value unlocking chemistry
In the domestic market, growth visibility for the subsidiary comes from capacity expansion plans of the company’s key clients – Indofil, UPL and Aarti industries
BUSINESS
Jackson Hole: A speech that can act as a preamble for central banks
The responsibility of central bankers to deliver price stability is unconditional.
BUSINESS
Hikal: Is the worst over?
The reopening of the Taloja plant should help the company consolidate business
BUSINESS
HEG: Traction in European demand key watch in the near term
While the quarterly performance was remarkable, near-term prospects are a bit subdued due to the lower demand in Europe.
BUSINESS
Divi’s Labs: Focus on green chemistry
The drug firm is set to benefit from investments in productivity and new product range
BUSINESS
Apollo Hospitals: What lends a hand to core business margins?
The healthcare business is back on track with increase in patient visits and elective procedures. Apollo Hospitals' business margins have been impressive and the occupancy rate is likely to reach pre-COVID levels.
BUSINESS
IPCA Labs: High-cost inventory a drag in the near term
Traction in domestic business but uncertainty in export side
BUSINESS
Amber Enterprises: Long runway for growth
The contract AC maker aims to grow faster than the industry average
BUSINESS
Zydus Lifesciences: Nephrology, biosimilar scope takes focus
Valuation reasonable on the back of traction in branded business
BUSINESS
Blue Star maintains margin discipline amid market uncertainty
Despite many challenges, Blue Star (BLSTR) outperformed its peers in terms of sales and margins in Q1FY23. Strong order inflows and improvement in operating margins, despite cost pressure, marks a strong beginning for fiscal 2023
BUSINESS
Laurus Labs: Diversification picks up pace
Near-term challenges with respect to supply are easing off
BUSINESS
Sun Pharma: Slowdown in speciality clinical trials needs to be watched
For FY23, we continue with the estimates that the top line of Sun Pharma would grow in a high single digit only
BUSINESS
Cipla: Watch out for respiratory and Peptide pipelines
Cipla is building its Peptide pipeline with the recently launched Lanreotide injection, which has been well received
BUSINESS
Dr Reddy’s: China, India to lead EM opportunity
The biggest focus area for Dr Reddy’s is Emerging Markets (EMs). Including India, EMs make up for 43 percent of its sales. In FY23, the company is targeting 130 launches in EMs, of which 30 would be for India
BUSINESS
As Fed reaches 'neutral rate', expect some softening in stance
The Fed continues to be “highly attentive to inflation risks” and determined to take the measures needed to bring down inflation to 2 percent goal
BUSINESS
Navin Fluorine: Diversification away from agrochemicals to set it apart
Navin Fluorine is increasingly looking towards fluoro applications in performance materials. Among the new product platforms to watch out for would be those of fluoropyridine
BUSINESS
SRF: Capex intensity in free flow
Among the recent announcements, what got our attention is more than 50 percent expansion for the belting fabrics capacity to cater to demand as infrastructure spend revives.
BUSINESS
Syngene: Multi-year contract with Zoetis adds to long-term visibility
The risk to watch is the execution in the field biologics and the pending regulatory approvals
BUSINESS
Gland Pharma: What do acute supply shortages mean for the business & investors?
In the medium to long term, upside triggers can come from biologics CDMO and China opportunity.
BUSINESS
Bhansali Engineering: Normalising margins, limited scope for volume growth cap earnings
The challenges to the auto end-market are showing signs of easing, but BEPL’s limited idle capacity restricts it from capitalising on the situation
BUSINESS
What does strength in dollar index mean for Indian equities?
One-month rolling return on the Dollar index is more than two standard deviation level higher from the average value of returns for last 20 years– the level at which it generally doesn’t stay long.
